Ischemic heart disease is a common consequence of coronary artery disease (CAD), which is primarily driven by atherosclerosis, a chronic inflammatory ...

A review of the side effects of CAR T-cell therapy, including CRS, ICANS, tumor lysis syndrome, and late-onset toxicities, and management strategies.

Early clinical results suggest the firm's antibodies targeting the Vβ T-cell receptor could induce strong and durable responses in cancer patients.

Macrophages interact with T cells in order to bring about T cell activation in target organs, and are themselves activated by inflammatory messenger molecules (cytokines) produced by the T cells.

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell ...

Discover how the ALA-CART platform enhances CAR T cell efficacy against antigen-low leukemias. With improved LAT activation, cytotoxicity, and persistence, ALA-CART offers a promising solution for ...

A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...